business
Novartis' Pipeline In Focus After A Series Of Clinical Setbacks

Novartis has come under increasing pressure after a series of clinical and pipeline setbacks in the second half of 2026, culminating in calls from a major shareholder for changes to the company's board.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Firebirds Wood Fired Grill Celebrates $5 Million Fundraiser Milestone in Longtime Partnership with Alex's Lemonade Stand Foundation to Fight Childhood Cancer
Businesswire

VICI Properties Inc. Formally Appoints John M. Sullivan to Board of Directors
Businesswire

Eastern Light Distilling Reaches Key Financing & Investment Milestones Propelling Future of Innovative New Kentucky Distillery
Businesswire

Upbound Group Names Scott Young as Chief Operating Officer and Dev Chakraborty as Head of Brigit
Businesswire

Choice Properties Real Estate Investment Trust Completes Issuance of $300 million of Series Y Senior Unsecured Debentures
Businesswire